Tag
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
Tag
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
2mo ago · 1 min · Technology
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
2mo ago · 1 min · Markets
— End of feed —